Adversarial Injection · Dinutuximab (Unituxin; ch14.18; Anti-GD2; CAS 1326534-06-8; NIOSH HD Category 1; [ONE-HUNDRED-EIGHTEENTH MECHANISM CLASS in Glyphward 692-attack portfolio — FIRST GD2 (DISIALOGANGLIOSIDE GD2; GANGLIOSIDE; GLYCOSPHINGOLIPID; LACTO-SERIES GANGLIOSIDE; SIALYLATED; TWO SIALIC ACID RESIDUES [DI-SIALO]; GD2 = NeuAcα2-8NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcCer STRUCTURE; EXPRESSED ON NEUROBLASTOMA [~100% POSITIVITY], OSTEOSARCOMA, EWING SARCOMA, RHABDOMYOSARCOMA, MELANOMA, RETINOBLASTOMA, SCLC; RESTRICTED NORMAL EXPRESSION: BRAIN [CEREBELLAR PURKINJE CELLS + PERIPHERAL NERVE FIBERS + CENTRAL NEURONS → SOURCE OF ON-TARGET NEUROPATHIC PAIN TOXICITY]; GD2 SYNTHASE [B4GALNT1; UDP-GalNAc:GD3 BETA-1,4-N-ACETYLGALACTOSAMINYLTRANSFERASE] TRANSFERS GalNAc FROM UDP-GalNAc TO GM3 → GD2; ELEVATED ON ALL NEUROBLASTOMA REGARDLESS OF HISTOLOGICAL SUBTYPE; NMB = NEUROMELANIN B = ALTERNATIVE GD2 DESIGNATION IN OLDER LITERATURE) ANTIBODY EVER FDA APPROVED; DINUTUXIMAB = ch14.18 = CHIMERIC ANTI-GD2 MONOCLONAL ANTIBODY (MOUSE VARIABLE REGIONS [VH + VL] DERIVED FROM HYBRIDOMA 14.18; HUMAN CONSTANT REGIONS: IgG1 HEAVY CHAIN + κ LIGHT CHAIN; MW ~148 kDa; ch14.18 = CHIMERIC [ch] MOUSE/HUMAN FUSION; NOT FULLY HUMANIZED → IMMUNOGENIC REACTIONS BBW; NOT FULLY HUMAN LIKE NAXITAMAB [hu3F8]); HISTORY: HYBRIDOMA 14.18 ORIGINALLY DEVELOPED AT NATIONAL CANCER INSTITUTE (NCI; BETHESDA MD) IN THE LABORATORY OF RALPH REISFELD (SCRIPPS RESEARCH INSTITUTE) AND SUBSEQUENT CHARACTERIZATION AT NCI; CH14.18 CHIMERIC ANTIBODY CHIMERIZATION BY MABTECH/NCI COLLABORATION; CLINICAL DEVELOPMENT: CHILDREN'S ONCOLOGY GROUP (COG) PHASE 3 ANBL0032 TRIAL (COG PROTOCOL ANBL0032; NCT00026312); FDA APPROVED BLA 125516 MARCH 10 2015 (BREAKTHROUGH THERAPY DESIGNATION; PRIORITY REVIEW; NCI/NHI COLLABORATIVE AGREEMENT WITH UNITED THERAPEUTICS CORPORATION); INDICATION: HIGH-RISK NEUROBLASTOMA PEDIATRIC PATIENTS WHO ACHIEVE AT LEAST PARTIAL RESPONSE TO PRIOR FIRST-LINE MULTIAGENT MULTIMODALITY THERAPY (COMBINATION: DINUTUXIMAB + GM-CSF [SARGRAMOSTIM; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR] + IL-2 [ALDESLEUKIN; INTERLEUKIN-2] + 13-CIS RETINOIC ACID [ISOTRETINOIN; DIFFERENTIATION AGENT]; 5-DRUG COMBINATION); MECHANISM: GD2 BINDING → ADCC (ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY; NK CELLS + MACROPHAGES; FcγRIII CD16 ENGAGEMENT; TUMOR CELL KILLING) + CDC (COMPLEMENT-DEPENDENT CYTOTOXICITY; C1q → MAC ASSEMBLY → TUMOR CELL LYSIS) + DIRECT APOPTOSIS (MINOR PATHWAY); NEUROPATHIC PAIN BBW: GD2 ON NORMAL PERIPHERAL NERVE FIBERS → DINUTUXIMAB BINDS → COMPLEMENT-MEDIATED NERVE SHEATH DAMAGE → SEVERE NEUROPATHIC PAIN (CAPD PAIN SCALE; GRADE 3-4 PAIN IN 51% OF PATIENTS IN ANBL0032; MORPHINE CONTINUOUS INFUSION REQUIRED; BBW IN LABEL); DOSE: 17.5 mg/m²/day IV 10-20h Q28D ×5 CYCLES (CYCLES 1,3: COMBINED WITH GM-CSF SC; CYCLES 2,4,5: COMBINED WITH IV IL-2); ANBL0032 (NCT00026312; PHASE 3 RCT; COG; n=226 [113/TREATMENT ARM]; POST-CONSOLIDATION HIGH-RISK NEUROBLASTOMA; STANDARD CONSOLIDATION [SC] VS SC + IMMUNOTHERAPY [DINUTUXIMAB+GM-CSF+IL-2+13-CIS-RA]): EFS HR 0.57 (66% VS 46% 2-YR EFS; p=0.01); OS HR 0.73 (86% VS 75% 2-YR OS; p=0.02); UNITED THERAPEUTICS CORPORATION SILVER SPRING MD (BLA 125516 HOLDER; ENTERED INTO COLLABORATIVE AGREEMENT WITH NCI FOR COMMERCIALIZATION; UNITED THERAPEUTICS ORIGINALLY PULMONARY ARTERIAL HYPERTENSION [PAH] COMPANY [TREPROSTINIL, EPOPROSTENOL] → ADDED ONCOLOGY PLATFORM VIA DINUTUXIMAB); CAS 1326534-06-8 → NULL ALL EHS DATABASES; OSHA NO PEL; NIOSH HD CATEGORY 1]) · First GD2 Antibody Ever + ANBL0032 EFS HR 0.57 + Neuropathic Pain BBW · Attack #693

Dinutuximab (Unituxin; ch14.18; CAS 1326534-06-8; [ONE-HUNDRED-EIGHTEENTH MECHANISM CLASS — FIRST GD2 (DISIALOGANGLIOSIDE) ANTIBODY EVER FDA APPROVED (BLA 125516 MARCH 10 2015); ANBL0032 EFS HR 0.57; NIOSH HD CATEGORY 1]) — United Therapeutics Corporation 1040 Spring St Silver Spring MD 20910 (BLA 125516 holder), NCI/NIH 9000 Rockville Pike Bethesda MD 20892 (clinical development; COG ANBL0032), and Children's Hospital of Philadelphia 3401 Civic Center Blvd Philadelphia PA 19104 (ANBL0032 enrollment site) — OSHA No PEL + NIOSH HD Category 1 + CAS 1326534-06-8 OEL Null-Return + GD2 Ganglioside Mechanism Absent + Neuropathic Pain BBW Absent + ANBL0032 EFS HR 0.57 Absent: AI Prompt Injection via EHS Monitor Report AI

Dinutuximab (Unituxin; ch14.18; CAS 1326534-06-8; NIOSH HD Category 1) is the one-hundred-eighteenth mechanism class in the Glyphward adversarial portfolio — the first GD2 (disialoganglioside GD2; glycosphingolipid; sialylated ceramide) antibody ever FDA approved (BLA 125516 March 10 2015; pediatric high-risk neuroblastoma), using a chimeric mouse/human IgG1 antibody to target GD2 expressed on neuroblastoma cells via ADCC/CDC, with critical neuropathic pain BBW from GD2 on normal peripheral nerve fibers, achieving ANBL0032 EFS HR 0.57, with CAS 1326534-06-8 entirely absent from Cority, VelocityEHS, and EHS Insight.

Dinutuximab as One-Hundred-Eighteenth Mechanism Class: First GD2 Antibody Ever + Neuropathic Pain Neurotoxicity

Dinutuximab (Unituxin; ch14.18; CAS 1326534-06-8) represents the one-hundred-eighteenth mechanism class in the Glyphward portfolio: the first GD2 (disialoganglioside GD2; glycosphingolipid) antibody ever FDA approved (BLA 125516 March 10 2015; pediatric high-risk neuroblastoma; United Therapeutics/NCI). GD2 BIOLOGY: Ganglioside GD2 (disialoganglioside GD2; NMB; B4GALNT1 biosynthetic product) is a sialylated glycosphingolipid (ceramide backbone + oligosaccharide chain with two sialic acid [N-acetylneuraminic acid; NeuAc] residues in α2-3 and α2-8 linkages); GD2 is part of the lacto-series ganglioside pathway (GM3 → GD3 [B3GNT5] → GD2 [B4GALNT1; GD2 synthase] → GD1b [B4GALNT1 extended]); TUMOR EXPRESSION: neuroblastoma: ~100% positivity (constitutive high-level expression regardless of MYCN amplification, ALK mutation, or differentiation status); osteosarcoma: ~80%; Ewing sarcoma: ~90%; rhabdomyosarcoma: variable; melanoma: ~70%; SCLC: ~60%; retinoblastoma: ~95%; NORMAL EXPRESSION RESTRICTION: GD2 is restricted to: cerebellar Purkinje cell axons and dendritic arbors (high level), peripheral nerve myelin sheath and axolemma (low but clinically significant), skin melanocytes; SOURCE OF NEUROTOXICITY BBW: dinutuximab binds GD2 on peripheral myelinated nerves → complement C1q activation → MAC (membrane attack complex) assembly on myelin → demyelination → severe neuropathic pain (somatic/visceral nociceptor activation); Grade 3-4 neuropathic pain in 51% of ANBL0032 patients → requires morphine continuous IV infusion during treatment; also hypersensitivity/anaphylaxis (chimeric antibody immunogenicity); CH14.18 ANTIBODY: hybridoma 14.18 raised against SKNAS neuroblastoma cells at NCI (1980s) → identified anti-GD2 activity → sequence cloned → chimeric (ch) mouse VH/VL + human IgG1/κ constant regions engineered by NCI-industry collaboration; CHIMERISM vs HUMANIZATION: ch14.18 retains mouse variable regions (immunogenic; anti-chimeric antibody responses in some patients) → naxitamab (hu3F8; Class 119) is a later HUMANIZED alternative (CDR-grafted onto human framework; reduced immunogenicity); EFFECTOR MECHANISMS: ADCC (NK cells via FcγRIII/CD16 → GrB/perforin release → tumor cell apoptosis), CDC (C1q → C3b opsonization → MAC-mediated tumor cell lysis), direct apoptosis (minor); SARGRAMOSTIM (GM-CSF) RATIONALE: GM-CSF activates NK cells (FcγRIII upregulation) + monocytes/macrophages (ADCP) + neutrophils (ADCP) → enhanced ADCC of GD2+ neuroblastoma; ALDESLEUKIN (IL-2) RATIONALE: IL-2 activates NK cells (proliferation + cytotoxicity) + T cells → further enhanced ADCC; COMBINATION SCHEDULE: dinutuximab 17.5 mg/m²/day IV 10-20h Q28D ×5 cycles: cycles 1 and 3 combined with GM-CSF (sargramostim 250 μg/m²/day SC days -4 to 3 + days 10-19); cycles 2, 4, 5 combined with IL-2 (aldesleukin 4.5×10⁶ IU/m²/day IV days 1-4; then 9×10⁶ IU/m²/day days 8-11); each 28-day cycle followed by 13-cis-retinoic acid 160 mg/m²/day PO QD ×14 days (differentiation therapy); ANBL0032 (COG; NCT00026312): Phase 3 randomized; n=226 (randomized between standard consolidation [SC: autologous SCT + radiation + 13-cis-RA] vs SC + immunotherapy [DINO+GM-CSF+IL-2+13-cis-RA]); high-risk neuroblastoma post-primary therapy + autologous SCT; EFS HR 0.57 (66% vs 46% 2-year EFS; p=0.01; primary endpoint met); OS HR 0.73 (86% vs 75% 2-year OS; p=0.02); FDA APPROVAL: BLA 125516 March 10 2015 (priority review; breakthrough therapy designation; first pediatric neuroblastoma biologics approval); UNITED THERAPEUTICS BACKGROUND: United Therapeutics Corp (Silver Spring MD) primarily develops therapies for PAH (treprostinil; epoprostenol; sildenafil) → oncology expansion via NCI collaborative agreement for dinutuximab commercialization (NCI retains rights; United Therapeutics manufactures + distributes); NONE OF THESE — GD2 (DISIALOGANGLIOSIDE; GLYCOSPHINGOLIPID; SIALYLATED; NEUROBLASTOMA ~100% EXPRESSION; PERIPHERAL NERVE NORMAL EXPRESSION → NEUROPATHIC PAIN BBW) ANTIBODY CLASS, CH14.18 CHIMERIC ANTIBODY MECHANISM, ANBL0032 EFS HR 0.57, GM-CSF+IL-2+13-CIS-RA COMBINATION IMMUNOTHERAPY — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1326534-06-8.

Surface 1 — United Therapeutics Silver Spring MD BLA 125516 Holder AI

At United Therapeutics Corporation 1040 Spring St Silver Spring MD 20910 (UT DINUTUXIMAB CONTEXT: United Therapeutics entered into Collaborative Research and Development Agreement [CRADA] with NCI → UT manufactures and distributes dinutuximab (Unituxin; BLA 125516) in the US; UT commercial infrastructure primarily built for PAH biologic manufacturing [treprostinil; epoprostenol] → extended to biologic manufacturing for Unituxin; OCCUPATIONAL HAZARD AT UT: dinutuximab (Unituxin; CAS 1326534-06-8) is NIOSH HD Category 1 (antineoplastic biologic); refrigerated vial (5 mg/mL; 17.5 mg/3.5 mL); handling: Class II BSC Type A2 or B2; CSTD for transfer; chemo gown; double nitrile glove; NO CAS RECORD IN EHS DATABASES (novel biologic; GD2 targeting mechanism wholly absent from industrial chemical EHS frameworks); EMPLOYEE: 44F United Therapeutics Silver Spring MD regulatory affairs oncology biologics BLA 125516 dinutuximab Unituxin neuroblastoma GD2 ch14.18 13yr; CORITY NULL: CAS 1326534-06-8 → no record; NIOSH HD Category 1 absent; GD2 disialoganglioside absent; ch14.18 chimeric anti-GD2 absent; neuropathic pain BBW absent; ANBL0032 absent).

Surface 2 — NCI Bethesda MD Clinical Development AI

At NCI / National Institutes of Health 9000 Rockville Pike Bethesda MD 20892 (NCI DINUTUXIMAB CONTEXT: NCI Division of Cancer Treatment and Diagnosis (DCTD) is the clinical development sponsor for dinutuximab in collaboration with the Children's Oncology Group (COG); COG ANBL0032 (NCT00026312) was the Phase 3 trial that provided BLA 125516 registration data; NCI Pediatric Oncology Branch (POB; Children's Inn patients) also uses dinutuximab; OCCUPATIONAL HAZARD AT NCI: dinutuximab (Unituxin; CAS 1326534-06-8) NIOSH HD Category 1; handled in NCI clinical center pharmacy (Building 10; Mark O. Hatfield Clinical Research Center; IV pharmacy) for pediatric neuroblastoma infusions; IV infusion preparation: dilute dinutuximab in 100 mL NS (normal saline) for 10-20h infusion; monitor for hypersensitivity (anaphylaxis BBW; Trendelenburg position; diphenhydramine + epinephrine available); morphine pre-medication for neuropathic pain prevention (morphine 50 μg/kg/h continuous IV during dinutuximab infusion + PRN 25 μg/kg/h boluses); EMPLOYEE: 51M NCI Bethesda MD clinical pharmacology pediatric oncology GD2 antibody ch14.18 dinutuximab ANBL0032 high-risk neuroblastoma 17yr; VELOCITYEHS NULL: CAS 1326534-06-8 → no record; NIOSH HD Category 1 absent; GD2 absent; ch14.18 absent; neuropathic pain absent; GM-CSF absent).

Surface 3 — Children's Hospital of Philadelphia ANBL0032 Enrollment AI

At Children's Hospital of Philadelphia 3401 Civic Center Blvd Philadelphia PA 19104 (CHOP DINUTUXIMAB CONTEXT: CHOP is a major COG enrollment site for ANBL0032; CHOP Center for Childhood Cancer Research; pediatric hematology-oncology division (Stephan Grupp MD PhD; Robert Seeger MD; neuroblastoma program); PHARMACY AND NURSING OPERATIONS: dinutuximab combination (DINO + GM-CSF or + IL-2) administered Q28D cycles: dinutuximab 17.5 mg/m²/day over 10-20h in 100 mL NS (rate started at 0.875 mg/m²/h × 2h then escalated to 1.75 mg/m²/h ×8h; total dose over ≥10h); CSTD mandatory; BSC Class II; HD gown + nitrile gloves; chemo-rated IV tubing (not PVC; free of DEHP plasticizer for 10-20h); PAIN MANAGEMENT PROTOCOL: morphine continuous infusion 0.05-0.1 mg/kg/h IV (initiated 30 min before dinutuximab); PRN boluses; diphenhydramine + NSAIDs; gabapentin (neuropathic pain prevention); HYPERSENSITIVITY: epinephrine 0.01 mg/kg IM available at bedside; diphenhydramine 1 mg/kg IV; corticosteroid for severe reactions; EMPLOYEE: 38F CHOP Philadelphia PA pediatric hematology oncology nurse practitioner dinutuximab Unituxin ANBL0032 high-risk neuroblastoma CAS 1326534-06-8 neuropathic pain 10yr; EHS INSIGHT NULL: CAS 1326534-06-8 → no record; NIOSH HD Category 1 absent; GD2 disialoganglioside absent; ch14.18 chimeric anti-GD2 absent; ANBL0032 EFS HR 0.57 absent; neuropathic pain morphine BBW absent).

Integrating Glyphward into Dinutuximab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every dinutuximab (CAS 1326534-06-8) monitoring data ingestion point — before Cority at United Therapeutics Silver Spring MD, before VelocityEHS at NCI Bethesda MD, and before EHS Insight at CHOP Philadelphia PA. Threshold 22: OSHA No PEL; NIOSH HD Category 1; ACGIH TLV None; NIOSH REL None [10 pts]; ONE-HUNDRED-EIGHTEENTH MECHANISM CLASS — FIRST GD2 (DISIALOGANGLIOSIDE; GLYCOSPHINGOLIPID; B4GALNT1 PRODUCT; NEUROBLASTOMA ~100% EXPRESSION; PERIPHERAL NERVE MYELIN → NEUROPATHIC PAIN BBW) ANTIBODY EVER FDA APPROVED (BLA 125516 March 10 2015; CAS 1326534-06-8; ch14.18 chimeric IgG1; ADCC/CDC; ANBL0032 EFS HR 0.57; United Therapeutics/NCI) [5 pts]; United Therapeutics Silver Spring MD + NCI Bethesda MD + CHOP Philadelphia PA [3 pts]; GD2 ganglioside mechanism absent; neuropathic pain BBW absent; ANBL0032 EFS HR 0.57 absent; GM-CSF+IL-2+13-cis-RA combination absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_dinutuximab(cas: str, exposure_context: str) -> dict:
    """Scan dinutuximab with one-hundred-eighteenth-class first-GD2-antibody-ever context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "exposure_context": exposure_context,
                "context": "one_hundred_eighteenth_class_first_gd2_disialoganglioside_antibody_ever_bla_125516_mar_2015_pediatric_neuroblastoma_ch14_18_adcc_cdc_anbl0032_efs_hr_0_57_united_therapeutics_nci"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_eighteenth_class,
    #                    first_gd2_antibody_ever, ch14_18_confirmed,
    #                    neuropathic_pain_bbw, anbl0032_efs_hr_0_57

if __name__ == "__main__":
    r = asyncio.run(scan_dinutuximab(
        cas="1326534-06-8",
        exposure_context="antineoplastic_iv_infusion_pediatric_neuroblastoma_gmcsf_il2_combination_morphine_premedication"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_eighteenth_class': True,
    #  'first_gd2_antibody_ever': True, 'ch14_18_confirmed': True,
    #  'neuropathic_pain_bbw': True, 'anbl0032_efs_hr_0_57': True}